Business Cases Are Optimised for Approval

Financial controls govern the money. They do not govern the delivery.

You have stage-gate funding in place. Milestone-based release. Reauthorisation thresholds. These are sound financial controls, and they are not the problem. The problem is that capital can be released on schedule while control failures accumulate silently underneath. The financial gate checks whether the conditions for release have been met on paper. It does not independently verify whether the program is actually capable of delivering the outcome the business case promised.

The business case itself is part of the problem. You have approved hundreds. Most overpromise on benefits and understate cost and complexity. This is not carelessness — business cases are constructed to secure funding, and the incentive structure produces exactly the optimism you have learned to distrust. But scrutinising the case more aggressively at approval does not solve this. The real exposures emerge during delivery, not during discovery, and by the time they surface in the reporting you receive, the capital is already committed and the options have narrowed.

The reporting compounds the issue. The people who wrote the business case are the same people reporting on whether delivery is tracking to plan. One program reports progress in narrative. Another uses a RAG. A third reports earned value. You cannot compare them. You cannot benchmark any of them against how programs of similar size and complexity actually performed elsewhere. Each one exists in isolation, assessed against its own optimistic baseline, and the result is that you are making capital allocation decisions across a portfolio where no two programs are measured the same way. You have asked for consistency. Every program manager reports in the framework they prefer, and the apples-to-oranges problem persists.

At $60,000 or more per engagement, ad-hoc Big-4 assurance reviews cannot be applied at every gate for every material program. You commission them selectively — on the highest-profile, highest-exposure investments — and the rest pass through with no independent verification. The gap between what full assurance costs and what stage gates actually require is where most capital allocation decisions are made without an independent evidence base.

An investment governance control, not a consulting engagement

ProjectPhD is an independent diagnostic designed to sit at the capital release gate as a standing control — embeddable across all material programs, not reserved for the ones large enough to justify a Big-4 fee.

Within 48 hours, you receive a Board Assurance Report that benchmarks the program against a matched peer cohort: programs of comparable size, sector, category, technology, and complexity, drawn from over 2,000 historical diagnostics. The benchmark is built on outcome data, not delivery team projections. Of those 2,000+ programs, 1,200 are coded against whether sponsors judged the program delivered to expectations and achieved its intended business outcomes. The comparison tells you how programs structurally similar to this one actually performed — a reference frame for the business case assumptions that does not originate from the team seeking your approval.

The output is a confidence score with its basis fully disclosed: respondent coverage, stakeholder alignment, attestation quality, and cohort match strength. This is not a binary red-amber-green assessment. It is a confidence interval with documented assumptions, structured for a capital allocation decision. A Benefits-at-risk indicator flags specifically where delivery failures threaten committed benefits realisation — cost overrun exposure, delayed return on investment, dependencies on milestones that are themselves at risk — before capital becomes irrecoverable.

The report produces a decision-grade recommendation: proceed, step-up discipline, or commission full assurance. Alongside the recommendation, conditions-to-proceed specify the requirements for responsible funding release — with owners, timeframes, and acceptance criteria. A Re-Check at 90 days confirms whether those conditions have been met, or escalates if they have not. The One-page Governance Decision Memo records the recommendation, confidence basis, methodology version, and conditions. It is an investment governance record at the point of capital release.

When embedded as a standard control across the portfolio, the diagnostic gives you what no amount of bespoke PM reporting currently provides: a consistent, comparable delivery confidence metric across all material programs, benchmarked against outcome data from structurally similar projects. The same instrument, the same methodology, the same benchmark — applied to every material capital commitment.

20-YEAR EMPIRICAL RECORD

Built on what programs actually delivered, not what they predicted

The benchmark dataset draws on 2,000+ diagnostics conducted over 20 years of program assurance practice — roughly a quarter in ERP and core systems, a fifth in regulatory change. Cohort matching operates across multiple axes so the comparison is against programs structurally similar to yours, not an undifferentiated average. Statistical regression is applied to calculate correlations and confidence levels. Where matching cohorts are thin, confidence intervals are widened and the limitation is disclosed. The methodology does not stretch beyond what the data supports.

Every recommended condition is drawn from the ProjectPhD Recommendations Library: interventions grounded in what boards and sponsors actually needed at the funding gate, and what happened in comparable programs where those conditions were absent. The methodology is standardised, versioned, and scored independently — no contingent fees, disclosed conflicts, second-review sign-off at higher tiers. Multi-respondent attestation corroborates the evidence base across roles rather than relying on any single account. The Alignment Index surfaces where stakeholder views diverge on delivery reality, documenting disagreement as an investment signal rather than a political finding.